PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Kintor Pharmaceutical Ltd (9939.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG5273B1077
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$384.85M
Revenue (TTM)HK$34.23M
Gross Profit (TTM)HK$34.23M
EBITDA (TTM)-HK$637.74M
Year RangeHK$0.83 - HK$6.58
Target PriceHK$12.56

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Kintor Pharmaceutical Ltd

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Kintor Pharmaceutical Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%40.00%NovemberDecember2024FebruaryMarchApril
-69.20%
16.41%
9939.HK (Kintor Pharmaceutical Ltd)
Benchmark (^GSPC)

S&P 500

Returns By Period

Kintor Pharmaceutical Ltd had a return of -49.69% year-to-date (YTD) and -86.47% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-49.69%5.29%
1 month-18.00%-2.47%
6 months-69.17%16.40%
1 year-86.47%20.88%
5 years (annualized)N/A11.60%
10 years (annualized)N/A10.43%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-25.77%8.26%-34.35%
2023-21.26%-4.38%-24.81%-17.26%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 9939.HK is 5, indicating that it is in the bottom 5% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of 9939.HK is 55
Kintor Pharmaceutical Ltd(9939.HK)
The Sharpe Ratio Rank of 9939.HK is 77Sharpe Ratio Rank
The Sortino Ratio Rank of 9939.HK is 11Sortino Ratio Rank
The Omega Ratio Rank of 9939.HK is 22Omega Ratio Rank
The Calmar Ratio Rank of 9939.HK is 44Calmar Ratio Rank
The Martin Ratio Rank of 9939.HK is 88Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Kintor Pharmaceutical Ltd (9939.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


9939.HK
Sharpe ratio
The chart of Sharpe ratio for 9939.HK, currently valued at -0.94, compared to the broader market-2.00-1.000.001.002.003.00-0.94
Sortino ratio
The chart of Sortino ratio for 9939.HK, currently valued at -2.56, compared to the broader market-4.00-2.000.002.004.00-2.56
Omega ratio
The chart of Omega ratio for 9939.HK, currently valued at 0.69, compared to the broader market0.501.001.500.69
Calmar ratio
The chart of Calmar ratio for 9939.HK, currently valued at -0.87, compared to the broader market0.001.002.003.004.005.00-0.87
Martin ratio
The chart of Martin ratio for 9939.HK, currently valued at -1.46, compared to the broader market0.0010.0020.0030.00-1.46
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.79, compared to the broader market-2.00-1.000.001.002.003.001.79
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.61, compared to the broader market-4.00-2.000.002.004.002.61
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.31
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.36, compared to the broader market0.001.002.003.004.005.001.36
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current Kintor Pharmaceutical Ltd Sharpe ratio is -0.94. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.94
1.77
9939.HK (Kintor Pharmaceutical Ltd)
Benchmark (^GSPC)

Dividends

Dividend History


Kintor Pharmaceutical Ltd doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.04%
-4.37%
9939.HK (Kintor Pharmaceutical Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Kintor Pharmaceutical Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Kintor Pharmaceutical Ltd was 99.04%, occurring on Apr 17, 2024. The portfolio has not yet recovered.

The current Kintor Pharmaceutical Ltd drawdown is 99.04%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.04%Sep 2, 2021644Apr 17, 2024
-66.33%May 25, 2020123Nov 19, 202079Mar 16, 2021202
-34.6%May 24, 202118Jun 17, 202123Jul 21, 202141
-24.9%Mar 23, 20213Mar 25, 202113Apr 16, 202116
-22.89%Jul 22, 20214Jul 27, 202126Sep 1, 202130

Volatility

Volatility Chart

The current Kintor Pharmaceutical Ltd volatility is 12.60%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%NovemberDecember2024FebruaryMarchApril
12.60%
3.39%
9939.HK (Kintor Pharmaceutical Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Kintor Pharmaceutical Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items